Case Control Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Nov 6, 2017; 8(4): 193-200
Published online Nov 6, 2017. doi: 10.4292/wjgpt.v8.i4.193
Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn’s disease
Ioannis Papaconstantinou, Christina Kapizioni, Evangelia Legaki, Elena Xourgia, George Karamanolis, Antonios Gklavas, Maria Gazouli
Ioannis Papaconstantinou, Antonios Gklavas, 2nd Department of Surgery, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece
Christina Kapizioni, Gastroenterology Department, Tzaneion General Hospital, 18536 Piraeus, Greece
Evangelia Legaki, Elena Xourgia, Maria Gazouli, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece
George Karamanolis, Gastroenterology Unit, 2nd Department of Surgery, Aretaieio Hospital, Medical School, National and Kapodistrian University of Athens, 11528 Athens, Greece
Author contributions: Papaconstantinou I, Kapizioni C, Karamanolis G and Gazouli M conceived and designed the study; Kapizioni C, Legaki E, Xourgia E, Gklavas A and Gazouli M acquired, analyzed, and interpreted data; Kapizioni C and Gazouli M wrote the original draft; Papaconstantinou I, Gazouli M and Karamanolis G reviewed, and approved the article.
Institutional review board statement: The study was reviewed and approved by the Aretaieio Hospital Institutional Review Board.
Informed consent statement: All study participants, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Maria Gazouli, Associate Professor, Laboratory of Biology, Medical School, National and Kapodistrian University of Athens, Michalakopoulou 176, 11527 Athens, Greece. mgazouli@med.uoa.gr
Telephone: +30-2107-462231 Fax: +30-2107-462231
Received: May 29, 2017
Peer-review started: June 8, 2017
First decision: August 8, 2017
Revised: August 21, 2017
Accepted: September 14, 2017
Article in press: September 15, 2017
Published online: November 6, 2017
Core Tip

Core tip: Anti-TNF agents are the cornerstone of inflammatory bowel disease (IBD) treatment strategy so far though not effective in one third of patients in the first months of administration. Biomarkers for prediction of each patient’s treatment response are vigorously sought in the era of personalized medicine. MicroRNAs have been studied as possible predictors of response to therapy in cancer and autoimmune diseases including IBD. MiRNA polymorphisms though have never been studied in IBD as markers of anti-TNF response. Our results suggest that for rs2910164, rs11614913, rs113054794, and rs188519172 no association to anti-TNF agents’ response in patients with Crohn’s disease can be established.